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Abstract
The need to find an efficient method to store gametes and embryos was driven both by
medical and agricultural necessities. Gametes were the first cells used in early attempts
of cryopreservation, yet these proved to be the most elusive. This chapter details the
story of the development of techniques for gamete and embryo freezing, starting with
hot air balloons and ending with cryotop open vitrification systems. Since gametes were
the first cells to be frozen and the last to successfully thaw, their story provides an
overview of the development of the science of cryopreservation.
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1. Introduction
The advent of embryo cryopreservation 25 years ago [1, 2] was revolutionary as well as critical
in reproductive medicine. Cryopreservation and storage of gametes and embryos provide cost
and procurement efficiencies in treatment options, which otherwise would be inaccessible
without substantial financial resources.
Cryopreservation maximizes fertility potential per retrieval cycle, providing a repository for
individual’s gametes/embryos that may not exist elsewhere. Thus reproductive potential is not
limited to reproductive years, but available as one manifests the need. Use of this technology
has paved the way toward single embryo transfer (SET), thereby decreasing the risk of multiple
gestation pregnancy and associated health risks.
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Additional application has unfolded to address needs associated with convenience and
transport for the purposes of using gestational carriers, family planning, travel, and using
donor oocytes/embryos in support of non-fertile couples in conception and familial continuity.
Advances in cryopreservation are paralleled and even rooted in key developments in assisted
reproductive technologies (ARTs). Historically, advanced culture techniques, complex culture
media, and supplements specific to the support of late stage embryonic development attempt-
ed to mimic in vivo conditions [3]. Together with carefully controlled culture environment,
blastulation rates have increased exponentially from decades prior [4, 5].
In addition to these supportive measures, newer technologies including time lapse morpho-
logical assessment allow for the development of observation-based algorithms as prognostic
indicators of embryonic competence. Collectively these factors form the paradigm in increased
opportunities for cryopreservation and subsequent improved selection criteria for single
embryo transfer. In fact, this is the current trend.
The goal of healthy ART outcome should not be clouded by commercial success rates, and
while not a mandate, single embryo transfer (SET) is now widely accepted as the default
position in good prognosis patients. According to a meta-analysis of randomized controlled
trials, SET versus double embryo transfer (DET) in a fresh In Vitro Fertilization (IVF) treatment
cycle resulted in a lower pregnancy rate, lower rate of multiple births and preterm birth, and
better odds of delivering a term singleton live birth. The reported SET versus DET pregnancy
rate disparity is virtually eliminated with an additional frozen SET cycle [6]. However, the
immediate consequence is that in order to achieve similar results, the patient may require/need
multiple cycles of embryo transfers.
Approximately 30–50% of embryos make it to a blastocyst stage. The average number of
embryos frozen per IVF cycle is age dependent: women of age >35 have fewer than two embryos
frozen, while younger women responding better to ovarian stimulation and producing more
eggs, result in a higher likelihood of having excess embryos available for freezing [7]. The
Department of Health and Human Services estimates that in 2015 more than 600K frozen
embryos were stored nationwide in the USA [8]. Figures for the year 2012 released by the
Human Fertilization and Embryo Authority (UK) report that of the >3.5 million embryos
created since 1991, 840K (24%) were cryopreserved for clinical use. In Canada, it is estimated
that >60K frozen embryos are in storage [9]. The current trend of freezing all the embryos with
no fresh embryo transfer [10] in IVF treatment would suggest these numbers will likely grow
much faster. Despite this uncertainty, these values underscore the importance of cryopreser-
vation technologies.
2. Historical perspectives
Since the discovery of the tissue preserving effect of low temperatures, it has been an aspiration
to maintain the vitality of human tissues by freezing. Soon after early attempts at tissue
cryopreservation had failed, the main hurdle in achieving this goal became apparent; water
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crystallizes upon freezing and the sharp edges of the crystals disrupt cell membranes and
destroy the cells. From that point onward the history of the study of cryopreservation is a
description of the relentless attempts to prevent intracellular crystallization at subzero
temperatures. This journey has been even more elusive for those trying to cryopreserve
oocytes.
It has been known for many centuries that subzero temperatures can preserve tissue, mostly
following the accidental discoveries of intact ancient animals frozen in ice for many years.
However, from studying patients inflicted by frostbite it was clear that freezing may also cause
tissue destruction [11].
2.1. Early days
Interestingly, the cells that were chosen for the early studies on the effects of freezing and
thawing on cell viability were gametes. Spermatozoa were chosen due to their availability,
small size, and their motility, which was a simple marker of viability. Oocytes were chosen
since their size is large enough to allow for simple morphological evaluation.
Spallanzani, in 1776, was the first to study the effect of subzero temperatures on stallion semen
and silkworm eggs [12]. He discovered that when thawed the sperm regained its motility. This
was the first report of a successful sperm freeze thaw. However, it was not until 1938 that Jahnel,
while searching for a remedy for syphilis, found that sperm cooled to −79°C for 40 days
regained some of its motility upon thaw and reinvigorated efforts to devise an efficient
freezing method [13].
Very early in the study of cryopreservation two opposing schools of thought had been
developed in parallel; slow freezing with gradual desiccation of the cell and ultra-rapid
freezing of small volumes also known as vitrification.
2.2. Vitrification
The term vitrification originates from the Latin word “vitreum” (glass) that describes the
transformation of a substance into a non-crystalline amorphous solid. The process commonly
involves rapid cooling of a liquid so that it passes through the glass transition to form a vitrified
solid.
The French, Joseph Luis Gay-Lusac, in 1804 ascended in a hot air balloon and noticed that the
water drops (size around 8–10 μm) in the clouds are not frozen despite the sub-zero temper-
atures (−5°C) [14]. He later went on to find that water can be subcooled to −12°C when contained
in small tubes [15]. In 1858, Albert J.R. Mousson, a Swiss physicist, had found that the smaller
the sprayed water droplets (diameter < 0.5 mm), the longer they can stay subcooled [16]. The
liquid state of the water droplets in subzero temperatures is attributed to rapid cooling forming
a non-crystalized solid. Luyet in his book coined the term “crystallization zone”, which relates
to the range of temperatures in which crystals form. He concluded that in order to avoid
crystallization one must traverse this zone faster than the time it takes to form crystals [14]. It
later became apparent that the small volumes are essential for achieving the high cooling
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velocity since it is proportional to the ratio of surface area to volume. It was also noticed that
different solutions of similar volumes cool at different rates. The concentration of the solutes
was shown to affect the “thermal mass (heat capacity)”, which represents the ability of a
substance to store thermal energy and is inversely proportional to the velocity of cooling. Pure
water has a very high heat capacity and therefore is almost impossible to cool fast enough to
exceed crystal growth unless very small volumes are used [17]. Walton and Judd measured
the velocity of ice crystal growth in undercooled water and found it to be 65 mm/s, thereby
providing the basis for calculation of the necessary speed of cooling to avoid crystallization
[18]. Fahy and Rall found that in order to vitrify pure water a cooling rate of 100 × 106oC/min
is necessary. Since such cooling velocities are not feasible, to achieve vitrification one needs to
increase to solute concentration (cryoprotectants) and reduce the solutions volume. This is the
current basis for clinically applied vitrification [19].
The work done by Luyet and Hodapp with colloid solutions (gelatin or agar) had led to the
first successful vitrification of sperm [20]. They were able to show that the water content of the
solutions was the determining factor on whether vitrification was achievable. With a 50%
gelatin solution they were able to vitrify layers of 0.3 mm; however, when using a 10% gelatin
solution, they could only vitrify a layer a few microns thick [15]. The drawback of these
concentrated solutions was their cell toxicity. Therefore, there is a need to balance the solutions’
cooling velocity on one hand and the solutes’ cell toxicity on the other. It was not until 1985
that an ice-free cryoprotectant system was developed that could attain vitrification and achieve
live birth for vitrified thawed mouse embryos [21–23]. Others were able to achieve high post-
thaw survival rates with vitrified hamster oocytes, as well as with immature and mature
murine oocytes [24–26].
Attempts to simplify the vitrification solution using a high concentration of a single cryopro-
tectant (dimethyl sulphoxide, DMSO) were initially successful for mouse and hamster oocytes,
but later proven to be toxic causing aneuploidy, malformations and a high rate of miscarriage
[27–30]. These publications halted further attempts to vitrify oocytes and focused the attention
on the alternative, slow freezing.
2.3. Slow freezing
Parkes et al., in 1945 discovered, accidentally, that the rate of cooling is associated with post-
thaw survival rate. They found that large containers used for freezing semen, in which, due
to the large volume, the rate of cooling is slower, gave the best post-thaw motilities [31].
Hence, opposite to vitrification, slower cooling rates were associated with better cell vitality.
The explanation for this observation was the physical principle of osmotic dehydration; as
ice crystals formed in the suspending solution, the relative concentration of solutes in the
unfrozen fraction of the solution increased and thereby increasing its osmolality. The cells
suspended in the solution will respond to the higher osmolality by losing water. Therefore,
slower cooling rates are associated with greater cellular dehydration and reduced risk of in-
tracellular ice crystals formation, leading to a better post-thaw viability. Further work by
Chang on rabbit ova recognized the importance of cooling rate on the maintenance of viabil-
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ity, the artificial activation of oocytes by rapid cooling and the achievement of litters from
embryos stored at 0°C [32, 33].
Mazur was the first to describe cell-specific optimal cooling rates [34]. He was able to formulate
an equation that was based on the rate at which the cells responded to osmotic pressure
(hydraulic conductivity) and the effect of temperature on the movement of water across the
cell membrane (temperature coefficient of water permeability) and could therefore predict
cell-specific optimal cooling rates. Leibo et al. constructed a graph describing cooling rate
against survival rate [35]. He showed over a 1000-fold difference in the optimal rate of cooling
between oocytes (0.3°C/min) and erythrocytes (1000°C/min) due to the oocytes low hydraulic
conductivity and high temperature coefficient of water permeability.
In order to guarantee ice crystal formation in the cryo-solution that will ensure the increase in
its osmolality and cell desiccation, a process of ice crystal seeding was developed [36].
Two groups worked in the early 1970s independently on slow freezing of embryos. Both groups
had published in 1972 the first survival of murine embryos after slow freezing [1, 2] and live
offspring [1]. Both groups used slow freezing and a cryosolution containing 1 mol/l of DMSO.
Wilmut and Rowson published in 1973 on the first farm animal (a calf) to be born after a transfer
of a frozen thawed embryo [37].
With the advent of clinical use of IVF at the beginning of the 1980s a significant effort was made
to optimize human embryo freezing in order to increase the efficiency of IVF by storing excess
oocytes and embryos. This came to fruition with the first pregnancies and birth from frozen
thawed embryos that were frozen using slow freezing and DMSO [38, 39]. Soon after, these
were followed by publications reporting on human live births subsequent to the use of other
cryoprotectants such as propanediol and sucrose. These methods proved to be more reliable
and more widely adopted [40–42]. The success of human embryo freezing ignited a public
debate on the ethics of embryo freezing. These ethical dilemmas prompted research on the
possibility of clinical application of oocyte freezing, which was deemed to be more ethically
acceptable.
In 1986, Chen reported a twin pregnancy following slow freezing of human oocytes with
DMSO [43]. Chen reported high post-thaw survival, fertilization and development rates of
oocytes frozen with this technique, however, attempts to replicate his success by others failed
[44–46]. Furthermore, in line with the observation in animals, a high proportion of thawed
human oocytes resulted in polyploid embryos [44, 47]. The poor results of oocyte cryopreser-
vation relative to the success with embryo freezing brought clinical oocyte freezing to a halt.
2.4. Cryoprotectants
A cryoprotectant is a substance used to protect biological tissue from freezing damage. Arctic
and Antarctic insects, fish and amphibians create cryoprotectants (antifreeze compounds and
antifreeze proteins) in their bodies to minimize freezing damage during cold winter periods.
Their exact mechanism of action is yet not fully understood. 1949, Polge et al., once again by
accident, discovered the cryoprotective effects of glycerol [48]. They found that the glycerol
solution protects from crystal formation during freezing by cellular dehydration. This
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discovery had led to successful semen storage of farm animals in 1953 and human sperm in
1964 [49]. Cryoprotectants are divided into two groups: intracellular (such as DMSO, glycerol
and propylene glycol) and extracellular (such as sucrose, polyvinyl pyrrolidone, hydroxyethyl
starch and dextran). One of their modes of action is lowering of the freezing point of the
solution. Use of an intracellular cryoprotectant such as DMSO will prevent intracellular ice
formation, while the seeding drives extracellular crystallization and the resulting increase in
the osmolality of the cryosolution leading to cellular dehydration [50]. Cryoprotectants may
also protect the cell membrane from the drastic changes occurring during the transition
between fluid and solid states. Cryoprotectants may, however, be toxic to the cells, therefore
over the years a relentless search for less toxic and efficient cryoprotectants ensued as well as
for protocols combining several cryoprotectants in order to reduce individual solute concen-
tration and the associated cell toxicity.
2.5. The return of vitrification
In 1985, Rall and Fahy were able to successfully vitrify a strew of a relatively large volume
(0.25 ml) containing mouse embryos with a mixture of DMSO, acetamide and polyethylene
glycol that was snap frozen in liquid nitrogen [22]. Shortly after the publication on the first
births from slow-frozen oocytes, the first pregnancy and live birth from vitrified oocytes was
published [51]. Developments that led to this breakthrough included the understanding that
the length of exposure of the cells to the vitrification solution should be minimized to reduce
toxicity [52], as well as replacing DMSO with ethylene glycol and mixtures of several cryo-
protectants [53]. These changes brought about successful vitrification of bovine, murine as well
as human oocytes with multiple live births [54–56]. These advancements were accompanied
by the development of appropriate carriers to facilitate rapid cooling such as open-pulled
straws [57], electron microscopy grids [55] and nylon loops [58]. By the end of the 1990s,
vitrification was applied to human embryos achieving live births with both blastocyst and
cleavage stage embryos [59, 60]. The vitrification of oocytes, despite these developments, was
lagging until the introduction of appropriate carriers. The development of Cryotop in Japan
was the breakthrough that allowed the adoption of oocyte vitrification into routine clinical
practice. It allowed for an extremely rapid cooling rate that was facilitated by a minimal volume
and resulted in a very high survival rate and live births [61–63]. A few methodological
modifications that were made to the kit simplified its use and supported its wide spread
distribution. Two large comparative studies established its lead role in oocyte cryopreserva-
tion [64, 65].
3. Cryopreservation protocols
Cryopreservation protocols are numerous and optimized for the cell type being frozen. These
protocols fall into two major categories: equilibrium freezing and non-equilibrium freezing.
Critical to either process is the partial elimination of water in the cell to avoid ice crystal
damage. This chapter focuses on the two main methodologies employed in freezing repro-
ductive cells.
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Conventional slow freeze methodology is characterized as equilibrium freezing. Cells are pre-
equilibrated in cryo-protecting agent (CPA) and gradual temperature depression in a control-
led rate freezer optimized for the cell type being frozen is initiated. As super-cooling is
achieved, a manual seeding process is required to initiate ice crystal formation outside of the
cell. Continuous equilibrium of the cells is achieved by increasing the osmotic gradient initiated
from the increasing proportion of ice in the surrounding medium. As a result, the cell dehy-
drates, thereby lowering the freezing point of the cell. At a point, with the cell being almost
devoid of water, ice crystal formation is negligent and freezing occurs. This method is viewed
as “forgiving” in practice, given increased pre-equilibration exposure times to relatively low
concentrations of CPAs and as such promotes efficiencies by accommodating batch freezing
of multiple samples.
As water excursion depends on the rate of cooling, risk can be mitigated. Rapid cooling can
trap excess water inside the cell, leading to the formation of intracellular ice crystals, whereas
slow cooling promotes high intracellular solute concentration by severe volume shrinkage.
Both have deleterious effects on the cell.
In addition, cells that are cooled slowly are susceptible to cryo damage. Mechanisms of cryo
damage include upregulation of heat and cold-shock proteins in response to cold tempera-
tures [66, 67]. Induction of apoptosis [68], a mechanism of cryo damage, may not be immedi-
ately visible but delayed for several hours as cells try to recover from such cryopreservation
stresses [69].
Largely contrasting this technology, non-equilibrium freezing was developed to overcome the
many shortfalls of slow freeze methodology. Cells exposed to (usually 7.5–10%) lower strength
cryoprotectant solution undergo dehydration and permeation with CPAs. Subsequent (30–
60 s) rapid exposure to higher (40%) hyperosmotic solution results in complete dehydration
of the cell. The sample is plunged directly into liquid nitrogen. This avoids deleterious ice
crystal formation with high concentrations of CPAs and supremely rapid cooling rates (15,000–
30,000°C/min). The extreme elevation in solution viscosity promotes solidification or a glass-
like, suspended state as opposed to crystallization. This method requires high level manual
dexterity, is labor-intensive, while offering decreased incubation times can consistently and
reliably accommodate only one sample being frozen at a time. Highly skilled technicians may
stagger multiple samples as per protocol, yet this leaves success rates subject to human
variation. As a benefit, this method is easily introduced without the need of expensive
equipment. Though unconventional, an added benefit is a comparable survival after repeat
vitrification and warming of the same sample [70, 71].
Recent technological advancement into this freeze methodology is semi-automated vitrifica-
tion. This platform allows simultaneous cryopreservation of up to four embryos in a closed
system, addressing the long-term debate of cross-contamination in shared liquid nitrogen.
Non-clinical preliminary data comparing GAVITM (Genea BIOMEDX) to commercial manual
method in mouse and donated human blastocyst stage embryos is promising [72]. Further
clinical evaluation and advancement to oocytes and all embryonic stages is under way. Given
success of this platform, process standardization demonstrating improved ART efficiencies
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may implore the few labs resistant to convert to vitrification technologies to reconsider; albeit
cost considerations excluded.
4. Cryo-protecting agents
The biophysical changes that take place during temperature depression, extracellular ice
formation and the creation of a potentially lethal hyperosmotic environment leads to further
dehydration of the cell. Termed “freeze dehydration” this effect is implicated in organelle
disruption and loss, as well as fusion or changes in cell membranes [73]. At more depressed
temperatures, the viscosity of the highly concentrated solution inside and outside of the cells
remains as a glassy matrix, which is relatively stable for long-term preservation.
Additional cell damage may be caused by intracellular ice formation, which is more prominent
during inappropriate rapid cooling as time might be insufficient for water to move down the
chemical potential gradient established by the difference in solution concentrations between
the two sides of the membrane. If a cell can be cooled to a ‘glass region’, under conditions
inhibiting ice crystal formation, successful preservation can be achieved. This is termed
vitrification as previously described.
While the methodologies of slow freeze and vitrification technologies may vary within clinics,
the underlying principles are fundamentally the same. Combinations of reagents provide a
delicate balance between the protective and toxic effects of CPAs aiming to maintain the
functional capacity of organelles, while avoiding the two main causes of cell death associated
with cryopreservation: solute toxicity [74] and ice formation [34].
CPAs are generally small molecular weight solutes with high aqueous solubility, bearing polar
groups that interact weakly with water [75]. CPAs act to (i) moderate the effects of the rising
solute (electrolyte) concentrations in the intra and extracellular environment, (ii) stabilize
intracellular protein structure and (iii) provide increasing viscosity during temperature
depression that may kinetically slow or inhibit ice crystal formation. There has been a myriad
of solutes that exhibit some CPA activity: amino acids (e.g. alanine, glycine, proline), amides
(e.g. acetamide, formamide), diols (e.g. 1,2-propanediol, ethanediol), sugars (glucose, lactose,
ribose raffinose, dextrans, hydroxyethyl starch), large polymers (polyethylene glycol, polyvi-
nylpyrrolidone, polyvinyl alcohol) and alcohols (methanol) although some at low efficiencies
[76, 77]. Modern cryopreservation protocols are largely based on few reported CPAs that are
considered moderately or very effective in preserving nucleated cells [78].
CPAs can also be deleterious as osmotic effects resulting in too rapid excursion of water across
a cell membrane can cause membrane rupture. Similarly, hydrogen bonding may disrupt the
hydration shell around macromolecules. Chemical toxicity of high concentrations of CPAs is
another cause for concern, largely in vitrification methods, the nature of which is not entirely
understood [79, 80]. The suggested protein denaturation effect, even DNA conformational
changes and fragmentation have been debated [80, 81]. Finally, CPAs have been shown to alter
cytoskeletal components in mammalian oocytes, particularly filaments and the meiotic spindle
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[82]. The reversibility of this disruption is concentration and CPA dependent and varies
amongst species [54, 83–85].CPA reagents are classified as permeating, non-permeating and
stabilizing.
Permeating cryoprotectants (e.g., glycerol, propane diol, dimethyl sulphoxide or ethylene
glycol) cross the cell membrane through an osmotic gradient displacing water. These agents
act to reduce ice crystallization and reduce cell dehydration but are toxic at higher concentra-
tions. More specifically, in vitrification, the role is to completely inhibit ice formation. Perme-
ating cryoprotectants also stabilize intracellular solutes which otherwise would be lethal in a
hyperosmotic state. A similar dehydration effect is mimicked in the extracellular environment
with temperature reduction promoting further dehydration. Dehydration is dependent upon
the rate of temperature depression and limited by the cell permeability to water [35, 86].
Non-permeating cryoprotectants are generally higher molecular weight polymers (e.g.,
sucrose, polyethylene glycol, polyvinylpyrrolidone, ficoll, dextran). These agents mimic the
dehydration mechanism of penetrating cryoprotectants but remain outside of the cell.
Generally, less toxic than penetrating cryoprotectants at the same concentration a successful
vitrification strategy is to create a mixture of non-toxic level of permeating cryoprotectant(s)
by the addition of non-permeating cryoprotectant. Interestingly as toxic effects of permeating
cryoprotectants have been shown to be at least somewhat biochemical and unique in action,
total molarity of a mixture may not be a reliable indicator of cryosolution embryotoxicity [53].
For application, CPAs are contained within a “carrier” solution that will help keep cells alive
during cryopreservation. They act to provide osmotic and physiological support and avoid
deviations from isotonicity, which could result in dehydration or swelling and burst of cells.
It is important to note that the efficacies of carrier solutions are unpredictable and vary based
on the individual or mixture of CPAs present [19].
Concern of long-term putative effects of these chemicals has paved the way for investigation
into and application of extracted or modified natural biological agents, which are evolutio-
narily found in extreme environments. While conventional cryoprotectants interact with water,
the application of uniquely acting, naturally based complementary agents, is an attractive
proposition.
Biological anti-freeze molecules of sorts (e.g., cyclohexanediol and polyvinyl alcohol) [87, 88]
selectively adsorb to the surface of ice crystals inhibiting ice crystal growth and ice re-
crystallization. Ice blockers, including polyvinyl alcohol and polyglycerol (i.e., X-1000 and
Z-1000) [89], specific to vitrification solutions act to prevent ice crystal formation. Together,
these agents may also play a role in potentially damaging re-crystallization of ice growth
during warming [90].
Ice-nucleating agents act to achieve deliberate ice growth in defined sites. This phenomenon
is largely important in intact tissues and organs where integrated cell cooperation is essential
to normal function. Unlike small tissue sections, organs are unable to effectively absorb
cryoprotectant solution by simply soaking in a solution. In the case of whole organs, intro-
duction of cryoprotectants by perfusion (through existing vasculature) is necessary. As
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perfusion, due to capillary distribution and time requirement of CPA diffusion, may not be
equivalent throughout a larger structure, random ice crystal growth can be lethal simply by
mechanical disruption. By achieving deliberate ice growth in specific sites, the damaging
effects of super‐cooling and likewise intracellular ice formation can be mediated and poten‐
tially avoided.
Lastly as organisms synthesize solutes and metabolites in response to cold survival strategies
(e.g., trehalose [91], glycerol [92], polyols [93, 94]), understanding how biological structures
interact with these mixtures may offer added benefits to current freezing regimes.
5. Slow freezing versus vitrification
To compare slow freeze technology to vitrification, the efficiencies of cryopreservation must
take into consideration several factors: (i) disparities in embryo quality between the “best”
freshly transferred embryo and subsequent frozen embryos; (ii) lab‐specific criteria for embryo
cryopreservation may foster higher implantation rates by discarding some reproductive
potential of lesser quality embryos; (iii) cryo‐survival should be defined in terms of complete
or partial survival and (iv) post‐thaw selection criteria for the transfer of cryopreserved
embryos.
Therefore, a randomized control study comparing slow freeze and vitrification protocols
would require standardization of protocol under optimal conditions with sibling specimens.
To add more complexity in comparative analysis are individual case variations, including age
discrepancies, effects of hormonal stimulation, supplementation, and endometrial priming, all
of which must be taken into account.
Despite these challenges in reviewing evidence based data, as a generality the technique of
vitrification has been preferentially adopted over the more traditional approach of slow
cooling.
Vitrification of oocytes [95, 96] and embryos of all stages has been shown to be superior to
slow freezing [6]. A large amount of clinical data suggest that one of the major consequences
of the intracellular damage to embryos from slow “conventional” freezing is decreased
survival as well as diminished implantation potential and outcomes when compared to
vitrification [97–99]. Despite lower survival rate, there are some data that suggest similar if
not improved implantation rate with slow freeze technology with fully intact good quality
day 3 embryos [100]. It is known that embryo survival is not an all or none phenomenon, and
therefore, comparison should be stratified on a similar quality basis.
The lack of homogeneity in some reported data is anticipated and may be due to laboratory
practice or clinic‐specific differences, as with other ART procedures.
As the majority of early vitrification was with cleavage stage embryos, it was recognized that
failure to develop to an expanded blastocyst stage was largely a consequence of chromosomal
compromise and inability to lead to a successful outcome. A bifurcated movement to karyotype
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embryos through pre-gestational genetic screening and cryopreserve blastocysts rather than
their cleavage stage counterparts is advantageous in the identification of embryo competence
and in reducing risk of miscarriage and chromosomal defects [101, 102]. This practice is
important in that common morphological parameters of blastocyst scoring are not related to
chromosomal status [101] and particularly for women of advancing maternal age [103].
Over the past decade, with vitrification, it has become a standard of practice to expect a post-
thaw survival of >90% [104, 105] and implantation and pregnancy potentials marginally
equivalent to fresh embryos [106–109].
Studies reveal longer gestational periods and heavier and healthier babies born as a result of
frozen embryos compared to their fresh counterparts [110]. It is not clear whether this is related
to cryotechnique or maternal factors [111]; but confirms the value of vitrification.
Reports of increased post-revitalization implantation potential over fresh counterparts [112]
may be a consequence of staggered embryo transfers in which embryo procurement and
implantation are performed in separate cycles. In this scenario, optimal synchronization and
endometrial receptivity may be achieved in contrast to the impact of high levels of hormones
present in harvesting cycles [113].
Success rates with vitrification supporting this revolutionary technology are not limited to
gametes and embryos; however, extend to gonadal tissues, and non-reproductive applications
including cornea [114], brain [115], heart [116], vascular [117] tissues, and cartilage [118]. The
permeation of larger tissue sections and even whole organs, e.g., ovaries [119–122], shows
promise in transplantation. Efficacy and potential of vitrification technologies as demonstrated
through such a broad spectrum of applications justify its utility and warrant further investi-
gation into enhanced cryopreservation potential.
Though the safety and efficacy of cryopreservation technologies is largely supported by current
success rate, however, some degree of uncertainty and challenge remains.
Human embryonic stem cells (hESCs) have been established from isolated inner cell masses
and more recently from single blastomeres obtained from cell stage embryos [123, 124]. The
systemic reporting of chromosomal abnormalities and the recurrent manner in which they
appear highlights the importance of understanding the underlying source [125]. In part, these
changes are ascribed to the cryopreservation method, “adaptive pressure to” or “lab-specific
variations in” cell culture [126–128] or are simply inherent to the cell itself [129–131]. Similarly,
IVF embryos may be associated with increased risk of epigenetic abnormalities. At least in the
case of hESCs, for cell line stability and quality assurance, the safety and efficacies of different
cytogenetic methodologies have been assessed as they relate to genomic integrity and chro-
mosomal stability [132]. As chromosomal instability is largely related to carcinogenesis, similar
investigation into embryo cryopreservation methods may provide insight into the quality and
safety of established cryopreservation protocols. Understandably, in as much as embryonic
culture periods are acute in length (as compared to hESCs), still, the long-term effects of even
small epigenetic changes are unknown.
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6. Trends in embryo storage
Worldwide, 1.5 million ART cycles are performed each year and this number continues to rise
[133]. Up to a third of patients who undergo IVF have supernumerary embryos that are
cryogenically stored. A case is made for the perpetually increasing reserve of embryos and
more importantly those of patients lost to follow up. For reasons undescribed here, these
embryos are termed “abandoned”.
At least in the USA, estimates provide that there are up to 1.4 million abandoned embryos
[134] and though unknown it is safe to assume this number dwarfs the combined world-
wide total. Even with permitting signed patient consents, clinics are hesitant to act and dis-
card unclaimed embryos, largely because of the lack of regulatory guidance [135], leaving
clinics vulnerable to unanticipated legal ramifications. Recently, several solutions have been
proposed.
Consideration of imposing strict time limits on storage, outlining relevant responsibilities
of fertility clinics and patients, and clarifying absolute guidelines related to unrestricted
utility of embryos in terms of donation for third party, teaching or research use must be
defined within a strict legal framework. Above all adequate long-term storage facilities are
lacking.
A somewhat limited solution supporting non-fertile couples in conception and familial
continuity is embryo donation. It is noteworthy to mention that cryopreservation has indirectly
found a place in a larger market in terms of the transport and exchange of all types of biological
samples. Initial concern over the sensitivity of microscopic volumes employed in vitrification
to potentially shifting conditions during shipment has largely been overcome by advanced
vapor shipping dewars, temperature monitoring, and precautionary handling.
Specific to embryo donation, ethical and genetic consequences of donation to related and
unrelated parties, including offspring, must be carefully considered. In addition, given lack of
restrictions on storage time limits, decades old donated embryos, thus far, may provide
relatively antiquated genetics which ultimately interfere with the natural evolution of the
population.
Similarly, in the case of multiple embryos donated to different parties, even a marginal risk of
unsuspecting, related siblings, procreating by chance may have devastating consequences for
the developing fetus. This is even more likely if embryos are donated to a clinic within the
same geographical region. As such, advanced screening methods prior to procreation and/or
pre-natal testing may be of benefit.
Contrary to this line of thought, in a separate context, in animal and cell line research laboratory
settings, recessive gene expression and cell line mutations confer an advantage for study
purposes and cryopreservation provides cell line stability against undesired changes induced
by adverse events or long-term culture [136].
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7. The thawing process
Given the worldwide exchange of reproductive cells, which is practically commonplace, IVF
labs generally house a repository of embryos cryopreserved with various methodologies and
formulations. The core responsibility of clinics is to ensure safety and best practice outcomes,
and this requires staff training and laboratory access to a myriad of cryopreservation formu-
lations and techniques.
In actual practice, IVF laboratories may permit revitalization of embryos using readily
available thaw solutions/protocols. This is in contrast to purchasing the specific formulations
matched to the cryopreservation solutions that the cells were frozen in. The impact of such
mix and match freeze/thaw practices on embryos/oocytes is largely unexplored and may be
quite significant given the unique actions of CPAs and unpredictability of carrier solutions
as previously described. Observed success may be due to the robustness of certain repro-
ductive cells and this may provide some artificial confidence in this regard. Prior to such
validation cross-use of combinations of cryoprotectant solutions should be approached with
caution.
The development of cryopreservation techniques has had immense impact across many
disciplines, most notably reproductive medicine. While significant advances have been made,
further advances are needed in the changing landscape of fertility. Cryopreservation has
allowed IVF to evolve into a medical procedure that is efficient, safe, readily accessible, and
relatively affordable.
8. Oocyte cryopreservation
While the cryopreservation of cleavage stage embryos has been a proven method for 20 years,
more recently, all pre-implantation stages of embryos, including oocytes, were shown to be
successfully frozen. Recent resurgence into oocyte freezing makes this application a notewor-
thy aspect of cryopreservation as it applies to clinical reproductive medicine.
Oocyte cryopreservation was initially focused on fertility preservation of females undergoing
gonadotoxic treatments. Further application circumvented restrictions imposed on embryo
freezing, which were largely a consequence of ethical, moral and legal boundaries barring
embryo cryopreservation. Similarly, viewed as insurance for individuals of advanced repro-
ductive age, oocyte banking for non-medical purposes, otherwise termed social egg freezing,
supports future fertility potential in an increasingly growing group.
Women delaying childbearing until age 35 are a growing group. A trend citing increasing
pregnancy rates in women in their thirties and forties is attributable to first births rather than
subsequent birth, and is more pronounced in women of higher education. Psychosocial issues
supporting delayed conception include parental financial stability, decreased marital discord,
and increased behavioral and cognitive test scores of offspring. These are compounded with
increased risk to mother and fetus including prenatal care requirements, fetal distress, preterm
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birth, neonatal intensive care admission, and morbidity to women of advanced maternal age
[137–140].
In the USA, first birth rates for women aged 35–39 generally increased from the mid-1970s to
2012, while steady increases for women aged 40–44 began later in the early-1980s [141]. While
the trend is not as dramatic in Canada, over the past two decades the average age for births to
first time mothers in 2011 had risen to over 30, the oldest age on record. The year 2015 marks
the first year that the average age of British women having children has passed 30 for the first
time. More women over 35 are now first time mothers than the under 25s in marked contrast
with the pattern as recently as 5 years ago [142]. This trend of women waiting longer to have
children is consistent across race and ethnicity [143].
The high success rate with egg donation confirms that egg quality, rather than uterine factors
associated with age, is the primary barrier to pregnancy in older women [144]. Progressively
by early 40s to age 43, the chance of becoming pregnant through IVF exponentially decreases
to near 5% and by age 45, the use of donor eggs is the only reasonable alternative. Despite these
dismal outcomes, many couples or single women in their early 40s will choose to accept the
lower chance of becoming pregnant and use their own eggs.
Egg freezing for preservation of fertility shows promise for success. Age remains a problem
faced by women interested in using elective egg freezing. As the age of women undergoing
egg freezing increases, the outcomes of assisted reproductive technology cycles utilizing their
frozen eggs become less favorable.
A non-discriminatory cost-basis analysis of otherwise healthy 25-year-old women foregoing
fertility until 40 revealed oocyte cryopreservation as cost-effective if IVF cycles exceeded
$22,000 [145]. A hypothetical decision tree surrounding elective oocyte cryopreservation with
procreation attempt at 3, 5, or 7 years after initial decision reveals greatest improvement in
probability of live birth occurring if oocytes are banked at 37; noting an additional $29,000 cost
per live birth in this group otherwise. However, highest probability of live birth was achieved
with oocyte cryopreservation <34 years of age with no cost benefit observed for 25–30 year old
age range delaying pregnancy to 40 years of age [146]. A separate analysis cites 36 years of age
as the upper cut-point of non-donor oocyte cryopreservation for “success versus failure”, with
vitrification technology superior to slow freeze methodology [147]. Although an absolute value
may not be identified for childbearing based on individual factors and resources, success
probabilities at 42 years of age declining to <5% may safely advocate against oocyte cryopre-
servation for women >42 years of age. These models may not be reflective of all patient
populations including elective, infertile, and cancer patients pursuing oocyte freezing, and
individualized analyses may provide a more discriminatory framework.
Fertility preservation for (non-)medical reasons is controversial and becoming increasingly
common [148]. Ethicists have upheld women’s reproductive freedom while pointing out
that the so-called social freezing merely postpones social problems, rather than solving
them. The real challenge is two-fold. There is a clear lack of information and inadequate
regulation.
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Success rates of frozen oocytes vary among clinics, and this is reflected in conflicting statistics
and the lack of a scientifically sound framework for patient education. Reports are as low as
10 and as high as 60% success rate. Access to data in establishing clinic‐specific reliable
predictors is lacking as individual clinics are limited in critical mass numbers to effectively
determine the feasibility of this relatively new technological offering.
Though it has been reported that rates of survival, fertilization, and implantation of “young”
cryopreserved oocytes fertilized with ICSI are comparable to those of fresh oocytes [149], limits
imposed by nature are a constraint lending to advance planning as egg quality decline begins
at age 30 and increases significantly after age 35. With respect to aging, this technique of
suspending the biological clock aiming to reconcile “personal and professional timelines” must
align with current limits of scientific technologies and should be critically discussed on a case‐
by‐case basis. Critics warn of bio‐objectification [150], where women could be even considered
unaware victims of “a commercially exploitative context, thus undermining rather than
expanding reproductive autonomy” [151].
An acceptable degree of success allowed regulatory bodies providing ART oversight including
ASRM, CFAS to lift the experimental designation of oocyte cryopreservation; albeit with
limited guidance. Still the majority of health care companies have yet to support elective oocyte
cryopreservation for purposes other than medical necessity. Select companies are leaders in
providing paid benefits for social egg freezing [152]. Mollifying procreation with career casts
light on the authenticity of this offering as the employment organization benefits by not
prioritizing the adjustment of the social framework of the employment organization to
incorporate motherhood. Rather opinions suggest these companies seek “a productive, not a
reproductive, workforce” [153].
This controversial interaction between technology and society shifts the attention from a
medical procedure to a social phenomenon, which needs to be analyzed within a regulatory
framework of bioethics, biopolicy, bioeconomy, and biolaw [154] with unbiased, validated
reporting. In this regard, men and women can make educated choices in life decisions to
harmonize personal, professional needs [155], and pregnancy.
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